Logo

Incyte Adds SNPs to Abbott Agreement, Signs LifeSeq Gold Deal with Vertex

Mar 10, 2000
Premium

P

ALO ALTO, Calif.--Incyte Pharmaceuticals announced that it has expanded its agreement with Abbott Laboratories to include access to Incyte’s in silico SNP program for an undisclosed amount. The program was developed using a proprietary algorithm to discover common DNA sequence variants by mining Incyte’s LifeSeq Gold database of human genes.

Separately, Vertex Pharmaceuticals announced that it has licensed LifeSeq Gold for use in small molecule drug discovery. The drug company will use the genomic information as part of its chemogenomics discovery effort, which seeks to rapidly and simultaneously design multiple lead classes of drugs directed at protein targets in gene families.

Filed under

Informatics
Breaking News
The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.